Arbutus Biopharma Corporation - Common Stock - Çeyreklik Bilanço (NASDAQ:ABUS) | MetaTrader

Tam grafiği aç Full chart

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

Haberler

Arbutus Biopharma kazancı $0,91 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Moderna's Quarterly Earnings Preview: What You Need to Know

Arbutus Biopharma kazancı $0,02 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Roivant Sciences hissesi 30,31 dolarda rekor kırdı

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Chardan, Moderna anlaşması sonrası Arbutus hisse tavsiyesini korudu

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang